EDERRA Launches Crowdfunding Campaign to Revolutionize Supplement Industry with First-Ever, Farm-to-Body Superfood Supplement




EDERRA Launches Crowdfunding Campaign to Revolutionize Supplement Industry with First-Ever, Farm-to-Body Superfood Supplement

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) — via IBN — EDERRA, the innovative wellness brand behind EMPWR+, the first-ever proprietary blend of a broccoli microgreens and Lion’s Mane mushroom supplement, is launching a crowdfunding campaign to invite early supporters, wellness advocates, and investors to become part owners in a Company that’s redefining the future of supplements.

In less than a year, EDERRA has grown from an idea rooted in personal health struggles to a fast-emerging brand with a bold mission: To disrupt the $150 billion supplement market with pure, local, functional ingredients—with a radically transparent, farm-to-body approach.

The $250,000 crowdfunding campaign will support the Company’s scale in production, national expansion, and deepen community impact—offering investors a unique opportunity to enter the ground floor of a movement backed by a clear vision and strong early traction.

“We’re not just building a supplement brand—we’re igniting a wellness movement,” said Vladi Delsoglio, CEO of EDERRA. “People want more than generic pills and powders. They want truth, results, and connection to where their health starts. That’s the promise of EDERRA.”

A Track Record of Momentum

EDERRA’s progress to date speaks volumes:

• Launched EMPWR+: The only supplement to combine broccoli microgreens and Lion’s Mane.
• Partnered with California’s largest microgreens farm for sustainable sourcing.
• Approved by top retailers like natural markets Jimbo’s and Frazier Farms.
• Distributed by Specialty Produce, San Diego’s leading organic food supplier.
• Featured in 12-plus restaurants, infusing dining with functional wellness.
• Formed strategic partnerships with luxury spas, wellness clinics, and corporate gifting companies.
• Gained support from top chefs, influencers, and CPG advisors.
• More than 65% of revenue from repeat customers.
• Key partner of many local health and wellness community events.
• Assembled a world-class team of scientists, creatives, and operators passionate about revolutionizing wellness through transparency and innovation

A Lifestyle, Not Just a Product

EDERRA isn’t just focused on Direct-to-Consumer (DTC) growth; the brand is also pioneering functional dining experiences and working with renowned chefs to bring superfoods into everyday meals. EDERRA’s team is exploring luxury wellness gifting for corporate programs—a space that’s ripe for disruption. The Company’s vision includes investing in new technologies, establishing partnerships to scale sales, and building a household name in functional wellness that is rooted in purity, science and sustainability.

Invest in the Future of Wellness

EDERRA’s crowdfunding campaign is hosted on https://wefunder.com/ederra, offering multiple investment tiers starting at $2,500, with perks like lifetime discounts, product bundles, farm visits, and even a 16-week Muay Thai wellness program with Martial Arts world champion and fitness expert, Mike Lemaire.

Investors receive a 10% discount SAFE (Simple Agreement for Future Equity), positioning them for a potential 7x return within 3 to 5 years, as the brand scales nationally.

“This is bigger than a product launch—it’s about changing how people nourish their bodies and trust their supplements,” said Delsoglio. “We’re proud to open this opportunity to the community that helped us get here.”

Learn More

To explore EDERRA’s campaign or request the investor pitch deck, visit https://wefunder.com/ederra or contact hello@ederralyfe.com.

About EDERRA

Founded in San Diego, EDERRA is the first farm-to-body supplement brand focused on purity, science and performance. Its flagship product, EMPWR+, combines fresh broccoli microgreens and Lion’s Mane mushrooms to support cognitive health, inflammation reduction, and longevity. EDERRA is committed to radical transparency, sustainable sourcing, and building a future where food is both functional and deeply nourishing.

Media Contact:
Vladi Delsoglio
Founder & CEO, EDERRA
Email: hello@ederralyfe.com
IG instagram.com/tryederra
Website: www.ederralyfe.com

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Tesonet invests in Lithuanian SportsTech startup FPRO




Tesonet invests in Lithuanian SportsTech startup FPRO

Tesonet is investing €2 million in the Lithuanian SportsTech startup FPRO. This is FPRO’s first round of outside investment, marking a new phase in its development. The funds will help the startup to leverage smart tech solutions to expand professional training opportunities in youth football worldwide.

A made-in-Lithuania solution for the global football market

FPRO is a SportsTech startup that is developing innovative football training solutions for children. Working in collaboration with UEFA-certified coaches and experts in sports science, FPRO has devised a unique interactive app for children ages 6 through 12. The app is designed to improve their technique, coordination and ball control skills.

Having founded the Football Pro Academy back in 2018, founders Ernestas Pilypas, Darius Jankauskas, and Vilius Petkevičius were forced to move operations online during the pandemic. This was the impetus behind the development of their digital product, which was released in 2022. The platform’s user base currently consists of 140,000+ children from the UK, Germany, the US, and other countries. Most of the company’s revenue comes from sales outside of their home market.

“Football is the most popular sport in the world, but the market is currently short on qualified coaches. We wanted to create a solution that would be accessible to everyone, regardless of their financial means or location. FPRO fills this gap by offering young athletes an accessible, tech-driven method geared towards raising their physical fitness and developing their personalities in a comprehensive way. It helps to build their self-confidence, discipline, and passion for football through a focused and personalised coaching process. We see Tesonet’s investment as confirmation that we’re on the right track,” said Vilius Petkevičius, co-founder of FPRO.

Ambitious partnership for innovation in children’s sports

“The sports technology market has enormous potential, and football unites billions of people worldwide. Given our substantial experience with SportsTech, the latest investment reflects our strategy to expand the sports innovation ecosystem while strengthening the community both in Lithuania and globally. This is a profitable and growing startup with a broad user base, an unstoppable team, and founders who are experts in their field. It’s a perfect combination, and one that mirrors our own values,” commented Tomas Okmanas, co-founder of Tesonet.

Tesonet co-founder Eimantas Sabaliauskas added: “When making a decision to invest, we consider not only market potential, but also a given team’s vision and ability to solve real problems on a global scale. FPRO has created a strong product, and our goal as investors is to help them not just financially but also in terms of strategy. We see clear synergies where our contribution could help them optimise business processes, develop new revenue streams, expand their user base, and further accelerate growth internationally.”

Another SportsTech investment in Tesonet’s portfolio

This is not our first venture in the sports vertical. In 2022, we acquired shares in BC Žalgiris Kaunas, helping the basketball club with its digital transformation and commercial expansion. Then in 2024, we invested in basketball club BC London Lions, aiming to promote the development of young talent and bolster the club’s competitiveness internationally.

ABOUT TESONET:

Tesonet is one of the largest venture builders and investors in the Baltic States. It houses globally recognized companies such as joint cybersecurity powerhouse Nord Security and Surfshark, a market-leading web intelligence collection platform Oxylabs, the fastest-growing brand among hosting providers Hostinger, nexos.ai – an AI orchestration platform, and others.

With over 3,500 in-house talents and a fully developed infrastructure, Tesonet supports, funds, and scales businesses globally. Since 2018, Tesonet has extended its reach by investing in successful ventures like Hostinger, Cast AI, Eneba, BC Žalgiris, London Lions, Artea, Zapp, Turing College, and others.

Tesonet is known for its innovative ecosystem and strong infrastructure, which support product development, testing, and global growth. The company is dedicated to advancing technological innovation and helping grow the broader ecosystem.

ABOUT FPRO:

FPRO is a sports technology startup dedicated to developing innovative training solutions for children’s football. Collaborating with UEFA-certified coaches and sports university experts, FPRO has created a unique interactive mobile app designed to help children aged 6–12 improve their technique, coordination, and ball control skills.Currently, the platform is being used by over 140,000 children across the United Kingdom, Germany, the United States, and other countries.

EDERRA Launches Crowdfunding Campaign to Revolutionize Supplement Industry with First-Ever, Farm-to-Body Superfood Supplement




EDERRA Launches Crowdfunding Campaign to Revolutionize Supplement Industry with First-Ever, Farm-to-Body Superfood Supplement

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) — via IBN — EDERRA, the innovative wellness brand behind EMPWR+, the first-ever proprietary blend of a broccoli microgreens and Lion’s Mane mushroom supplement, is launching a crowdfunding campaign to invite early supporters, wellness advocates, and investors to become part owners in a Company that’s redefining the future of supplements.

In less than a year, EDERRA has grown from an idea rooted in personal health struggles to a fast-emerging brand with a bold mission: To disrupt the $150 billion supplement market with pure, local, functional ingredients—with a radically transparent, farm-to-body approach.

The $250,000 crowdfunding campaign will support the Company’s scale in production, national expansion, and deepen community impact—offering investors a unique opportunity to enter the ground floor of a movement backed by a clear vision and strong early traction.

“We’re not just building a supplement brand—we’re igniting a wellness movement,” said Vladi Delsoglio, CEO of EDERRA. “People want more than generic pills and powders. They want truth, results, and connection to where their health starts. That’s the promise of EDERRA.”

A Track Record of Momentum

EDERRA’s progress to date speaks volumes:

• Launched EMPWR+: The only supplement to combine broccoli microgreens and Lion’s Mane.
• Partnered with California’s largest microgreens farm for sustainable sourcing.
• Approved by top retailers like natural markets Jimbo’s and Frazier Farms.
• Distributed by Specialty Produce, San Diego’s leading organic food supplier.
• Featured in 12-plus restaurants, infusing dining with functional wellness.
• Formed strategic partnerships with luxury spas, wellness clinics, and corporate gifting companies.
• Gained support from top chefs, influencers, and CPG advisors.
• More than 65% of revenue from repeat customers.
• Key partner of many local health and wellness community events.
• Assembled a world-class team of scientists, creatives, and operators passionate about revolutionizing wellness through transparency and innovation

A Lifestyle, Not Just a Product

EDERRA isn’t just focused on Direct-to-Consumer (DTC) growth; the brand is also pioneering functional dining experiences and working with renowned chefs to bring superfoods into everyday meals. EDERRA’s team is exploring luxury wellness gifting for corporate programs—a space that’s ripe for disruption. The Company’s vision includes investing in new technologies, establishing partnerships to scale sales, and building a household name in functional wellness that is rooted in purity, science and sustainability.

Invest in the Future of Wellness

EDERRA’s crowdfunding campaign is hosted on https://wefunder.com/ederra, offering multiple investment tiers starting at $2,500, with perks like lifetime discounts, product bundles, farm visits, and even a 16-week Muay Thai wellness program with Martial Arts world champion and fitness expert, Mike Lemaire.

Investors receive a 10% discount SAFE (Simple Agreement for Future Equity), positioning them for a potential 7x return within 3 to 5 years, as the brand scales nationally.

“This is bigger than a product launch—it’s about changing how people nourish their bodies and trust their supplements,” said Delsoglio. “We’re proud to open this opportunity to the community that helped us get here.”

Learn More

To explore EDERRA’s campaign or request the investor pitch deck, visit https://wefunder.com/ederra or contact hello@ederralyfe.com.

About EDERRA

Founded in San Diego, EDERRA is the first farm-to-body supplement brand focused on purity, science and performance. Its flagship product, EMPWR+, combines fresh broccoli microgreens and Lion’s Mane mushrooms to support cognitive health, inflammation reduction, and longevity. EDERRA is committed to radical transparency, sustainable sourcing, and building a future where food is both functional and deeply nourishing.

Media Contact:
Vladi Delsoglio
Founder & CEO, EDERRA
Email: hello@ederralyfe.com
IG instagram.com/tryederra
Website: www.ederralyfe.com

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

LuminX Secures $5.5M to Revolutionize Warehouse Operations with Vision Language Models (VLMs) on the Edge




LuminX Secures $5.5M to Revolutionize Warehouse Operations with Vision Language Models (VLMs) on the Edge

San Francisco, June 02, 2025 (GLOBE NEWSWIRE) — LuminX, an AI-driven company pioneering cutting edge inventory automation and visibility, announced today the closure of its $5.5 million seed funding round. This initial funding will accelerate the development and deployment of its solutions for the logistics and warehousing industry. 

The seed round was supported by a multitude of investors, including 1Sharpe, GTMFund, 9Yards, Chingona Ventures, and the Bond Fund. LuminX addresses critical inefficiencies in supply chain and warehouse management that lead to significant operational costs and errors. The company is at the forefront of solving these issues by developing and deploying its Vision Language Models (VLMs) directly onto low-cost mobile hardware within the warehouse – an approach that makes advanced AI accessible and practical for a wider range of operations.

LuminX founders: Alex Kaveh Senemar and Reza Javanmardi.

LuminX systems uniquely integrate sophisticated visual understanding with powerful generative AI capabilities, enabling its cameras to ‘see’ and interpret complex, dynamic warehouse environments in real-time—recognizing products, varied labels, assessing package conditions, and tracking movement. These versatile devices can be deployed anywhere in the warehouse, including docks, conveyors, on forklifts, or as handheld units. LuminX’s system intelligently processes this visual information to automate intricate operational tasks, eliminate manual work, and provide actionable data for drastically reducing discrepancies and optimizing overall workflow.

LuminX is led by founder and CEO Alex Kaveh Senemar, a seasoned entrepreneur with a proven track record of building and scaling successful AI companies across several industries. He previously founded and led Voxel (voxelai.com), a pioneering AI company in warehouse safety and operations, and prior to that, founded Sherbit, which was successfully acquired by Huma (huma.com) in 2019. He is joined by co-founder & CTO Reza (Mamrez) Javanmardi, Ph.D. in Computer Science and former Head of AI Research at Voxel, whose career spans impactful R&D in machine learning and computer vision across startups and research institutions.

LuminX dashboard.

The LuminX team brings a wealth of knowledge and deep expertise in AI, specifically in Vision Language Models, computer vision, and robotics, with many members having ties to leading research institutions like Carnegie Mellon University. The team’s established track record and vision have garnered strong support. Significant participation in the funding round also came from previous investors in Voxel and customers, underscoring deep confidence in LuminX’s advanced technological approach.

“This pivotal funding allows us to scale our next-generation AI models, transforming how warehouses operate,” said Alex Kaveh Senemar. “Our edge based vision language models represent a massive step forward, acting as an intelligent core for warehouse operations. They deliver new levels of automation and insight, helping to turn previously opaque processes into transparent highly efficient systems.”

LuminX is experiencing strong early traction, with many warehouses using the technology. One such early adopter is Vertical Cold Storage. Robert Bascom, COO of Vertical Cold Storage, commented on their experience: “LuminX’s technology is set to revolutionize our warehouse productivity and operations. It’s allowing us to automate critical tasks, significantly enhance quality, and reduce claims.” He added, “In my entire career, I have yet to encounter a product that so effectively improves efficiency while simultaneously boosting quality and reliability.”

Kat Collins of 1Sharpe Capital, a key investor, echoed this sentiment, stating, “Edge-deployed vision-language models are breaking the two toughest bottlenecks in logistics—labor scarcity and data blindness. By turning a low-cost camera into a perceptive co-worker that sees, understands, and acts in real time, LuminX is unlocking a step-change in operational intelligence and efficiency for every pallet, conveyer, and forklift.”

The newly acquired funds will be strategically invested in advancing LuminX’s core research and development in Vision Language Models for logistics, further optimizing them for edge deployment, expanding its specialized engineering talent, and scaling go-to-market activities.  

Ends

Media images can be found here.

About LuminX
LuminX is dedicated to solving complex inventory management challenges by pioneering the application of Vision Language Models (VLMs) on edge devices within warehouses. The company provides innovative solutions that offer intelligent automation and real-time visibility, helping businesses to significantly reduce costs, improve accuracy, and streamline their warehouse and logistics operations by removing manual work. Learn more at luminxai.com

CONTACT: For more information please contact the LuminX press office on media@luminxai.com 

LuminX Secures $5.5M to Revolutionize Warehouse Operations with Vision Language Models (VLMs) on the Edge




LuminX Secures $5.5M to Revolutionize Warehouse Operations with Vision Language Models (VLMs) on the Edge

San Francisco, June 02, 2025 (GLOBE NEWSWIRE) — LuminX, an AI-driven company pioneering cutting edge inventory automation and visibility, announced today the closure of its $5.5 million seed funding round. This initial funding will accelerate the development and deployment of its solutions for the logistics and warehousing industry. 

The seed round was supported by a multitude of investors, including 1Sharpe, GTMFund, 9Yards, Chingona Ventures, and the Bond Fund. LuminX addresses critical inefficiencies in supply chain and warehouse management that lead to significant operational costs and errors. The company is at the forefront of solving these issues by developing and deploying its Vision Language Models (VLMs) directly onto low-cost mobile hardware within the warehouse – an approach that makes advanced AI accessible and practical for a wider range of operations.

LuminX founders: Alex Kaveh Senemar and Reza Javanmardi.

LuminX systems uniquely integrate sophisticated visual understanding with powerful generative AI capabilities, enabling its cameras to ‘see’ and interpret complex, dynamic warehouse environments in real-time—recognizing products, varied labels, assessing package conditions, and tracking movement. These versatile devices can be deployed anywhere in the warehouse, including docks, conveyors, on forklifts, or as handheld units. LuminX’s system intelligently processes this visual information to automate intricate operational tasks, eliminate manual work, and provide actionable data for drastically reducing discrepancies and optimizing overall workflow.

LuminX is led by founder and CEO Alex Kaveh Senemar, a seasoned entrepreneur with a proven track record of building and scaling successful AI companies across several industries. He previously founded and led Voxel (voxelai.com), a pioneering AI company in warehouse safety and operations, and prior to that, founded Sherbit, which was successfully acquired by Huma (huma.com) in 2019. He is joined by co-founder & CTO Reza (Mamrez) Javanmardi, Ph.D. in Computer Science and former Head of AI Research at Voxel, whose career spans impactful R&D in machine learning and computer vision across startups and research institutions.

LuminX dashboard.

The LuminX team brings a wealth of knowledge and deep expertise in AI, specifically in Vision Language Models, computer vision, and robotics, with many members having ties to leading research institutions like Carnegie Mellon University. The team’s established track record and vision have garnered strong support. Significant participation in the funding round also came from previous investors in Voxel and customers, underscoring deep confidence in LuminX’s advanced technological approach.

“This pivotal funding allows us to scale our next-generation AI models, transforming how warehouses operate,” said Alex Kaveh Senemar. “Our edge based vision language models represent a massive step forward, acting as an intelligent core for warehouse operations. They deliver new levels of automation and insight, helping to turn previously opaque processes into transparent highly efficient systems.”

LuminX is experiencing strong early traction, with many warehouses using the technology. One such early adopter is Vertical Cold Storage. Robert Bascom, COO of Vertical Cold Storage, commented on their experience: “LuminX’s technology is set to revolutionize our warehouse productivity and operations. It’s allowing us to automate critical tasks, significantly enhance quality, and reduce claims.” He added, “In my entire career, I have yet to encounter a product that so effectively improves efficiency while simultaneously boosting quality and reliability.”

Kat Collins of 1Sharpe Capital, a key investor, echoed this sentiment, stating, “Edge-deployed vision-language models are breaking the two toughest bottlenecks in logistics—labor scarcity and data blindness. By turning a low-cost camera into a perceptive co-worker that sees, understands, and acts in real time, LuminX is unlocking a step-change in operational intelligence and efficiency for every pallet, conveyer, and forklift.”

The newly acquired funds will be strategically invested in advancing LuminX’s core research and development in Vision Language Models for logistics, further optimizing them for edge deployment, expanding its specialized engineering talent, and scaling go-to-market activities.  

Ends

Media images can be found here.

About LuminX
LuminX is dedicated to solving complex inventory management challenges by pioneering the application of Vision Language Models (VLMs) on edge devices within warehouses. The company provides innovative solutions that offer intelligent automation and real-time visibility, helping businesses to significantly reduce costs, improve accuracy, and streamline their warehouse and logistics operations by removing manual work. Learn more at luminxai.com

CONTACT: For more information please contact the LuminX press office on media@luminxai.com 

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights




Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness

HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2025, and provides an overview of recent and upcoming business highlights.

“We improved our cash position in the first quarter as a result of both a financing and grant support,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “With the additional cash and further anticipated grant support in 2025, we are well positioned to make solid progress in our 2 key business goals: enrollment in our REYOBIQ™ CNS cancer radiotherapeutic clinical trials and the planned launch of the CNSide® cerebral spinal fluid (CSF) assay platform.”

Q1 2025 & RECENT HIGHLIGHTS AND MILESTONES

Corporate

• Raised gross proceeds of $15 million in a private placement financing – along with a $2.0 million grant award advance from the Company’s existing grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to accelerate development of REYOBIQ for our leptomeningeal metastases (LM) program.
• Added industry veteran Kyle Guse to the Board of Directors – Mr. Guse brings 30 years of professional experience in multiple executive roles, including as a Chief Financial Officer and a General Counsel of innovative companies.
• Strengthened management team with addition of Dr. Michael Rosol as Chief Development Officer – Dr. Rosol will lead the Company’s clinical, pre-clinical, and biomarker development activities.

REYOBIQ™ Clinical Trials

• Presented updated interim data on its lead compound REYOBIQ™ at the Nuclear Medicine and Neuro-oncology conference held May 9-10, 2025 in Vienna, Austria that highlighted the safety and clinical benefit of REYOBIQ™ in patients with LM.
• Published Phase 1 clinical trial results for REYOBIQ™ in peer-reviewed publication Nature Communications, demonstrating safety and potential efficacy in treating recurrent glioblastoma (GBM), with patients receiving a radiation dose >100 Gy achieving a median overall survival of 17 months, more than double the standard of care. Additional details can be found here.
• Completed ReSPECT-LM Phase 1 single dose administration trial and determined the maximum tolerated and recommended Phase 2 dose. Additional details can be found here.
• Granted U.S. FDA Orphan Drug Designation for REYOBIQ™ for the treatment of LM in patients with lung cancer.
• Received U.S. FDA conditional agreement for the proprietary name REYOBIQ™ for the Company’s lead radiotherapeutic, rhenium Re¹⁸⁶ obisbemeda.

CNSide™ CSF Assay Platform

• Strengthened management team with key leadership appointments:
  • Russell Bradley as President and General Manager of Plus Therapeutics’ wholly owned subsidiary, CNSide Diagnostics, LLC (“CNSide Diagnostics”) – Mr. Bradley provides leadership to CNSide Diagnostics with an immediate focus on commercialization of the CSF assay platform.
  • Dr. Jonathan Stein as Medical Director, CNSide Diagnostics – Dr. Stein provides technical leadership to support the CNSide™ CSF assay platform.

Q1 2025 FINANCIAL RESULTS

• The Company’s cash balance was $9.9 million at March 31, 2025 compared to $0.1 million at December 31, 2024.
• The Company recognized $1.1 million in grant revenue in the first quarter of 2025 compared to $1.7 million in in the first quarter of 2024, which represents CPRIT’s share of the costs incurred for our REYOBIQ™ platform advancement for the treatment of patients with LM.
• Total operating loss for the first quarter of 2025 was $3.5 million compared to $3.3 million in the same period of 2024. The increase is primarily due to increased legal fees.
• Net loss for first quarter of 2025 was $17.4 million, or $(1.19) per share, compared to a net loss of $3.3 million, or $(0.75) per share, for the same period the prior year.

About Plus Therapeutics®
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.

About REYOBIQ™ (rhenium 186re obisbemeda)

REYOBIQ™ (rhenium 186re obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ™ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).

About CNSide Diagnostic, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide™, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide™ CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. The Company is planning to commercialize CNSide™ in the U.S. in 2025.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

These statements include, without limitation, statements regarding the potential promise of REYOBIQ™, expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of REYOBIQ™ including through evaluations in additional patient cohorts; and expectations regarding receipt of grant funds.

The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the Company’s ability to maintain the listing of its common stock on Nasdaq; risks related to a halt in trading or delisting of the Company’s common stock on Nasdaq; the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact

CORE IR
investor@plustherapeutics.com 

Unbound raises $4M to help enterprises embrace AI tools on their terms




Unbound raises $4M to help enterprises embrace AI tools on their terms

Led by Race Capital, the round backs a new category of infrastructure that makes AI safe, observable, and governable inside large organizations

San Francisco, May 29, 2025 (GLOBE NEWSWIRE) — Generative AI tools have become ubiquitous in the enterprise. Employees are using AI copilots to code, draft documents, brainstorm campaigns, and analyze data – often without IT’s knowledge or approval. As adoption spreads from the bottom-up, companies are losing control over how sensitive information is being handled, what models are being used, and who has access to what.

Unbound has raised $4 million to fix this. The oversubscribed seed round was led by Race Capital, with participation from Wayfinder Ventures, Y Combinator, Massive Tech Ventures and others include notable angel investors*. 

Unbound Security founders: Vignesh Subbiah and Rajaram Srinivasan. 

Unbound gives IT teams the visibility and controls they need to safely introduce and manage AI tools in the enterprise. Its AI Gateway plugs into commonly used tools – like Cursor, Roo, Cline or internal document copilots – and provides real-time protection, model routing, and usage analytics. From blocking sensitive information leakage to managing model costs and performance, Unbound helps organizations roll out AI on their terms.

The founding team brings deep experience in both enterprise security and infrastructure. CEO and co-founder Rajaram Srinivasan previously led data security products at Palo Alto Networks and Imperva, and earlier worked on SaaS security at the onset of the AI wave. He teamed up with Vignesh Subbiah, a seasoned engineer and former founding team member at Tophatter and Shogun, who scaled engineering teams and platforms from seed to growth stage. After working together at Adobe, the two reconnected to build a system that could meet the urgent security gaps emerging in the new AI stack.

The need became clear quickly. In the early days of GPT-3.5, teams were already sending sensitive prompts into AI tools without oversight – leaking secrets, exposing PII, and consuming costly licenses with no guardrails. Existing DLP tools either blocked the tool altogether or failed to adapt to newer AI workflows.

Unbound takes a different approach. It has already prevented the leakage of 100s of secret credentials – including passwords, API keys, and connection strings – as well as more than 500 instances of personally identifiable information such as customer names, phone numbers, and patient records. Rather than simply blocking prompts, Unbound redacts sensitive content in real time and reroutes high-risk requests to internal, open-source models hosted in the organization’s cloud. This ensures employees get their answers without ever seeing a security speed bump.

Unbound: analytics dashboard.

The platform also gives companies fine-grained control over model access and cost. Rather than buying a one-size-fits-all license, teams can allocate premium model access to high-stakes workflows – like engineers building core infrastructure – while routing lighter tasks, like content editing, to smaller open-source models. Mid-market customers using Unbound have already saved more than $10,000 annually on unnecessary AI seat licenses. And when new models outperform old ones – as with Gemini 2.5 recently overtaking Claude Sonnet for certain coding tasks – Unbound allows IT to roll them out incrementally, test their effectiveness, and swap them in without breaking employee workflows.

The product is already being used by a growing base of mid-market and enterprise customers across sectors including tech and healthcare. One customer, a leading tech company, recently used Unbound to safely introduce Gemini 2.5 into production AI tools for more than 100 engineers within the same week.

“As AI tools become mainstream, enterprises are turning to flexibility and control,” said Rajaram Srinivasan, co-founder and CEO of Unbound. “They want visibility into what’s being used, assurance that their data is protected, and the ability to swap in better models as the space evolves. Unbound is the bridge that makes that possible.”

Reflecting on Unbound’s early days, CTO and co-founder Vignesh Subbiah said, “Defaulting to blanket bans on AI tools is like being in the times of GPT 3.5. Unbound enables surgical security controls into every AI request so teams can innovate freely without putting corporate secrets at risk.” He added, “In just a few months, our customers have prevented over 7,000 potential data leaks and cut AI tooling costs by nearly 70 percent.”

The market is shifting fast. What started as shadow IT is quickly becoming mission-critical infrastructure. Generative AI is embedded in everything from customer support to software engineering – but the tooling around it is still stuck in early-stage chaos. CIOs and CISOs are looking for ways to support AI adoption without compromising security or governance. Unbound is building that foundation. “At THG Ingenuity, we see the security team as an enabler, not a blocker. Unbound empowers us to roll out AI tools to employees with confidence. Unbound AI Gateway’s data protection controls and intelligent routing have been instrumental in safeguarding sensitive data while helping us optimize costs.” says Abraham Ingersoll, Chief Information Security Officer (CISO) of The Hut Group. The Hut Group (THG) is a customer of Unbound.

Unbound: usage analytics.

“AI is projected to reach $4.8 trillion in market value for the enterprise by 2033 globally — but without proper guardrails, that value is at risk. From shadow models to data leaks, the dangers of unmanaged AI are very real.  We are excited to back Rajaram Vignesh and the Unbound Security team as they create a new category of AI infrastructure: one built for safety, observability and cost discipline from day one.” said Edith Yeung, General Partner at Race Capital. “We’re proud to back Rajaram, Vignesh, and the team building a new category of AI infrastructure – one that makes enterprise adoption safe, observable, and cost-efficient from day one.”

Unbound is just getting started. The team plans to expand integrations across the AI ecosystem, deepen model routing capabilities, and support internal model orchestration for enterprises adopting open-source LLMs. Their mission is simple: to ensure every organization can embrace AI without losing control in the process.

* Other investors in the round included: Alpha Square Group, Northside Ventures, Liquid2, Pioneer Fund, Scale Asia Ventures, SBXI and notable angels including Ram Shriram (founding board member at Google), Dr. Trishan Panch (CSO LuminHealth), Dr. John Brownstein (Chief Innovation Officer, Boston Children’s hospital), Taro Fukuyama (CEO, Fond), Eli Brown (CEO, Guilded, acquired by Roblox), Chris Siakos (CEO Sinefa, acquired by Palo Alto Networks), Joe Vadakkan (CISO, Ex- CRO), Zain Rizavi (Cloudflare, Ridge VC), Finbarr Taylor (CEO, Shogun) alongside other silicon valley and cybersecurity veterans.

Ends

Media images can be found here. 

About Unbound
Unbound helps enterprises adopt Generative AI tools securely and responsibly across their organizations. As companies increasingly explore the benefits of AI, Unbound ensures that IT and security teams maintain the oversight they need. Unbound provides detailed visibility into usage patterns, helps control the flow of sensitive data, and enables policy enforcement to align with organizational standards. Unbound makes enterprise AI adoption safer, more transparent, and easier to manage.

CONTACT: For further information please contact the Unbound press office: media@unboundsecurity.ai  

HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design




HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design

The company has developed the first-ever platform to unlock precision control over glycans, essential sugar molecules found on the surface of a therapeutic. This innovation paves the way for safer, more potent therapeutics for cancer and chronic autoimmune diseases.

Paris, May 28, 2025 (GLOBE NEWSWIRE) — One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company kyron.bio today announced a €5.5 million funding round to solve these issues using precise control of sugar molecules found on the surface of a drug – also known as glycans. 

The seed funding round was led by HCVC, with the participation of Verve Ventures, Entrepreneurs First, Saras Capital, and numerous reputable angel investors. The funds will accelerate the development of kyron.bio’s proprietary glycan-engineering platform, expand the kyron.bio team and fuel preclinical studies. Additionally, the funding coincides with the launch of the company’s EIC Transition project, backed by the European Innovation Council.

kyron.bio team.

The company’s vision is to open a new design space for next-generation therapeutics using glycans and to partner with pharmaceutical companies to develop safer, more potent treatments for patients. kyron.bio focuses its technology specifically on antibody therapeutics, a majorly important class of drugs that harness the precision of the immune system to treat a wide range of diseases, including cancer and autoimmune diseases.

The problem with current antibody therapeutics: The patient’s body attacks the therapy
One of the major problems with antibody therapeutics is the patient’s immune system recognizing the treatment as foreign and attacking it. This immune response can be harmful and render the therapeutic ineffective. As drug design becomes more complex and therefore more foreign to the human immune system, this issue is an increasing burden to biopharma companies

This unwanted immune attack is problematic for patients, particularly those with chronic diseases that are treated over a long period of time. It also prevents many novel therapies from making it through the critical Phase I stage of clinical trials, where drug safety is assessed.

kyron.bio’s solution: Precision control over glycans to prevent unwanted immune attack
kyron.bio has pioneered a platform to fully control the process of N-glycosylation, the cellular mechanism that adds glycans to the surface of therapeutics. In standard biomanufacturing, this process is highly inconsistent, producing a mix of glycan structures that can trigger immune responses or reduce therapeutic efficacy. kyron.bio’s breakthrough enables, for the first time, the precise use of specific glycans to prevent unwanted immune attack. This platform is offered as a scalable, plug-and-play solution compatible with standard biopharma manufacturing techniques.

This breakthrough consists of two key elements:

1. Novel engineered cell lines: Genetic manipulation of the cells used as production factories (known as Chinese Hamster Ovary cells) to produce antibodies to enable, for the first time, complete control over the glycosylation process. 
2. Proprietary glycan-engineering toolbox: Engineering of the antibody therapeutic itself to prevent unwanted immune attack and enhance performance, while generating strong new intellectual property (IP).

Together, these technologies allow kyron.bio’s platform to achieve over 97% consistency in glycan structures – an unprecedented level compared to standard bioproduction methods.

This level of glycan control unlocks transformative opportunities in antibody engineering, enabling biologic therapies that can resist degradation, evade immune detection, and target diseases with unprecedented specificity. 

Dr. Emilia McLaughlin, CEO & Founder of kyron.bio.

The opportunity to partner with kyron.bio on drug design is especially pertinent to pharmaceutical companies working on next-generation monoclonal antibodies. These therapeutics often involve complex designs and multiple targets, which carry a higher risk of immune attack. 

In chronic conditions, such as autoimmune diseases, kyron.bio’s technology unlocks the possibility for more patients to receive treatment lifelong, without developing resistance to the therapy, which is sadly the case for many patients today. In oncology, this technology massively increases the chance of drugs passing the critical Phase I stage of development, where drug safety is evaluated.

Challenges like increasing therapeutic complexity and long-term treatments have made immune attack a growing obstacle. kyron.bio’s technology is designed to overcome these issues, paving the way for therapies that can reach more patients and perform better over time. Ultimately, this technology aims to unlock new treatment avenues for patients.

Alexis Houssou, Founder & Managing Partner at HCVC, said: “kyron.bio’s technology bridges a massive gap in therapeutics design. Their breakthrough in glycan control could shift the paradigm for antibody therapies, and we’re proud to support their vision.”

Dr. Emilia McLaughlin, CEO & Founder of kyron.bio, said: “To date, glycans have been massively under-exploited, limiting their potential in drug design. By achieving comprehensive control over glycosylation in a fully scalable manner, we have unlocked the possibility to use precision glycosylation in drug design. This transforms glycans into a design tool for the first time, opening up new treatment avenues for patients. Securing this fundraising round brings us closer to our goal of delivering precision glycan-engineered therapeutics to patients.”

Dr. McLaughlin’s experience studying rare single-cell organisms during her PhD at Institut Pasteur Paris has largely informed kyron.bio’s approach to drug development. The startup, under her leadership, has developed the first-ever scalable, patent-protected method to unlock this molecular design problem.

Ends

Media images can be found here. 

About kyron.bio
kyron.bio, based at Paris Biotech Santé in the Cochin Hospital, pioneers precision control of glycosylation in antibody therapeutics to enhance functionality. Leveraging both proprietary cell-based systems and structure-guided design, the company unlocks the untapped potential of N-glycans in oncology, autoimmune diseases, infectious diseases, and beyond. Learn more at http://www.kyron.bio.

About HCVC
HCVC is an early-stage deeptech venture capital firm that backs founders turning frontier science into foundational industries. HCVC invests in pre-seed and seed-stage companies across Europe and the US, with offices in Paris, London, and the Bay Area. The portfolio spans transformative sectors like frontier biotech, defense, AI infrastructure, robotics, climate, and space. Learn more at https://www.hcvc.co/

CONTACT: For further information please contact Emilia McLaughlin on hello@kyron.bio

HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design




HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design

The company has developed the first-ever platform to unlock precision control over glycans, essential sugar molecules found on the surface of a therapeutic. This innovation paves the way for safer, more potent therapeutics for cancer and chronic autoimmune diseases.

Paris, May 28, 2025 (GLOBE NEWSWIRE) — One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company kyron.bio today announced a €5.5 million funding round to solve these issues using precise control of sugar molecules found on the surface of a drug – also known as glycans. 

The seed funding round was led by HCVC, with the participation of Verve Ventures, Entrepreneurs First, Saras Capital, and numerous reputable angel investors. The funds will accelerate the development of kyron.bio’s proprietary glycan-engineering platform, expand the kyron.bio team and fuel preclinical studies. Additionally, the funding coincides with the launch of the company’s EIC Transition project, backed by the European Innovation Council.

kyron.bio team.

The company’s vision is to open a new design space for next-generation therapeutics using glycans and to partner with pharmaceutical companies to develop safer, more potent treatments for patients. kyron.bio focuses its technology specifically on antibody therapeutics, a majorly important class of drugs that harness the precision of the immune system to treat a wide range of diseases, including cancer and autoimmune diseases.

The problem with current antibody therapeutics: The patient’s body attacks the therapy
One of the major problems with antibody therapeutics is the patient’s immune system recognizing the treatment as foreign and attacking it. This immune response can be harmful and render the therapeutic ineffective. As drug design becomes more complex and therefore more foreign to the human immune system, this issue is an increasing burden to biopharma companies

This unwanted immune attack is problematic for patients, particularly those with chronic diseases that are treated over a long period of time. It also prevents many novel therapies from making it through the critical Phase I stage of clinical trials, where drug safety is assessed.

kyron.bio’s solution: Precision control over glycans to prevent unwanted immune attack
kyron.bio has pioneered a platform to fully control the process of N-glycosylation, the cellular mechanism that adds glycans to the surface of therapeutics. In standard biomanufacturing, this process is highly inconsistent, producing a mix of glycan structures that can trigger immune responses or reduce therapeutic efficacy. kyron.bio’s breakthrough enables, for the first time, the precise use of specific glycans to prevent unwanted immune attack. This platform is offered as a scalable, plug-and-play solution compatible with standard biopharma manufacturing techniques.

This breakthrough consists of two key elements:

1. Novel engineered cell lines: Genetic manipulation of the cells used as production factories (known as Chinese Hamster Ovary cells) to produce antibodies to enable, for the first time, complete control over the glycosylation process. 
2. Proprietary glycan-engineering toolbox: Engineering of the antibody therapeutic itself to prevent unwanted immune attack and enhance performance, while generating strong new intellectual property (IP).

Together, these technologies allow kyron.bio’s platform to achieve over 97% consistency in glycan structures – an unprecedented level compared to standard bioproduction methods.

This level of glycan control unlocks transformative opportunities in antibody engineering, enabling biologic therapies that can resist degradation, evade immune detection, and target diseases with unprecedented specificity. 

Dr. Emilia McLaughlin, CEO & Founder of kyron.bio.

The opportunity to partner with kyron.bio on drug design is especially pertinent to pharmaceutical companies working on next-generation monoclonal antibodies. These therapeutics often involve complex designs and multiple targets, which carry a higher risk of immune attack. 

In chronic conditions, such as autoimmune diseases, kyron.bio’s technology unlocks the possibility for more patients to receive treatment lifelong, without developing resistance to the therapy, which is sadly the case for many patients today. In oncology, this technology massively increases the chance of drugs passing the critical Phase I stage of development, where drug safety is evaluated.

Challenges like increasing therapeutic complexity and long-term treatments have made immune attack a growing obstacle. kyron.bio’s technology is designed to overcome these issues, paving the way for therapies that can reach more patients and perform better over time. Ultimately, this technology aims to unlock new treatment avenues for patients.

Alexis Houssou, Founder & Managing Partner at HCVC, said: “kyron.bio’s technology bridges a massive gap in therapeutics design. Their breakthrough in glycan control could shift the paradigm for antibody therapies, and we’re proud to support their vision.”

Dr. Emilia McLaughlin, CEO & Founder of kyron.bio, said: “To date, glycans have been massively under-exploited, limiting their potential in drug design. By achieving comprehensive control over glycosylation in a fully scalable manner, we have unlocked the possibility to use precision glycosylation in drug design. This transforms glycans into a design tool for the first time, opening up new treatment avenues for patients. Securing this fundraising round brings us closer to our goal of delivering precision glycan-engineered therapeutics to patients.”

Dr. McLaughlin’s experience studying rare single-cell organisms during her PhD at Institut Pasteur Paris has largely informed kyron.bio’s approach to drug development. The startup, under her leadership, has developed the first-ever scalable, patent-protected method to unlock this molecular design problem.

Ends

Media images can be found here. 

About kyron.bio
kyron.bio, based at Paris Biotech Santé in the Cochin Hospital, pioneers precision control of glycosylation in antibody therapeutics to enhance functionality. Leveraging both proprietary cell-based systems and structure-guided design, the company unlocks the untapped potential of N-glycans in oncology, autoimmune diseases, infectious diseases, and beyond. Learn more at http://www.kyron.bio.

About HCVC
HCVC is an early-stage deeptech venture capital firm that backs founders turning frontier science into foundational industries. HCVC invests in pre-seed and seed-stage companies across Europe and the US, with offices in Paris, London, and the Bay Area. The portfolio spans transformative sectors like frontier biotech, defense, AI infrastructure, robotics, climate, and space. Learn more at https://www.hcvc.co/

CONTACT: For further information please contact Emilia McLaughlin on hello@kyron.bio

London’s Startup Ecosystem Sees Major Leap in Global Rankings




London’s Startup Ecosystem Sees Major Leap in Global Rankings

LONDON, Ontario, May 26, 2025 (GLOBE NEWSWIRE) — London’s thriving startup ecosystem has earned global recognition again. In the newly released Global Startup Ecosystem Index 2025  by StartupBlink, London has climbed an impressive 165 spots globally. Nationally, the city has moved up to the 12th position, overtaking Hamilton (13th), Saint John (14th), Winnipeg (15th), and Fredericton (16th).

This jump in ranking reflects massive momentum in London’s tech and innovation ecosystem, driven by ambitious founders, visionary industry leaders, collaborative public-private partnerships, and sustained support from champions like TechAlliance of Southwestern Ontario. The annual Global Startup Ecosystem Index benchmarks over 1,000 cities worldwide, tracking performance across innovation infrastructure, startup activity, and international competitiveness—offering a vital dashboard for measuring industry health and progress.

“Recognition on this global index is a testament to the ambition of our startup founders and the strength of our innovation economy,” said Christina Fox, Chief Executive Officer at TechAlliance of Southwestern Ontario. “Coupled with London’s position as #4 on CBRE’s report on Top Emerging Tech Markets in North America, the StartupBlink index amplifies the region’s acceleration, and its global position, fortifying London, Ontario as one of the best places in Canada to become a unicorn. As the lead voice for the industry, TechAlliance fosters a vibrant tech community, empowering the growth of competitive, world-class ventures that drive economic prosperity here in Southwestern Ontario, while also shaping and fueling Canada’s innovation economy.”

In 2024, Canada attracted $8.8 billion USD in funding and was home to 22 unicorn companies. While the nation experienced a slight dip—falling from 4th to 5th place in the global rankings—the Global Startup Ecosystem Index points to strong fundamentals and an optimistic future, especially as efforts shift toward producing startups with greater international competitiveness. That growth starts at the regional level.

Doubling down on investor, founder and industry engagement, with a mandate to accelerate the growth of tech companies in Southwestern Ontario, TechAlliance supports entrepreneurs and their companies with strategic advisory, investment-readiness, storytelling, and advocacy. This approach not only builds a highly competitive local economy but also positions the greater London area as a key Canadian contributor on the global innovation map.

For more information or media inquiries, please contact:    
Farida Abdelnabi    
Communications Manager   
TechAlliance of Southwestern Ontario    
647.676.2461    
farida.abdelnabi@techalliance.ca    
   
About TechAlliance of Southwestern Ontario    
Headquartered in London, Ontario – one of the top ten emerging tech markets in North America, TechAlliance is the lead voice for the most promising startups and highest potential scaling companies in Southwestern Ontario. Home to a concentration of made-in-Canada unicorns, and supporting pathways to capital, customers, and talent, TechAlliance empowers world-class ventures and fuels growth in Canada’s innovation economy by supporting founders and ventures at every stage of the entrepreneurial journey.

As the place for dreamers, innovators, and world-changing ideas, TechAlliance fosters a vibrant tech community for founders, industry leaders, tech talent, and capacity builders, champions and coaches entrepreneurs, and amplifies and impacts businesses across the region. Funded in part by the Government of Ontario, Regional Innovation Centres help Ontario-based innovators and entrepreneurs clear commercialization hurdles –- accelerating the growth of companies so that they can compete and succeed globally and create high quality jobs in our province.